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The rational development of new diagnostic or prognostic tumour
markers and the identification of novel cellular targets for anti-
cancer chemotherapy relies on a more definitive understanding
of tumour biology. Classical approaches using cellular pharma-
cology, and more recently molecular pharmacology, have led to
the discovery of a number of growth factors and their receptors as
well as other proteins which has resulted in novel therapies (e.g.
inhibitors of epidermal growth factor receptor tyrosine kinase) and
prognostic markers (e.g. oestrogen receptor levels in breast
cancer) (Levitzki et al, 1995; Dowsett et al, 1997). Using classical
metaphase cytogenetic techniques, many chromosomal aberra-
tions have been identified in human cancer cell lines and primary
culture of haematological malignancies. This chromosomal infor-
mation has facilitated identification of a number of impor–
tant genes associated with tumorigenesis (e.g. loss of
chromosomal material on 13q led to identification of tumour
suppressor gene RB1; Vogel, 1979). However, the use of
metaphase cytogenetic analysis has been limited in solid tumours,
mainly due to the difficulties in growing primary cultures in which
to generate tumour metaphase chromosomes. However, this
changed with the development of comparative genomic hybridiza-
tion (CGH) and its ability to globally assess the genome of solid
tumours for areas of loss and/or gain without the need for tissue
culture (Kallioniemi et al, 1992; Forozan et al, 1997; Ried et al,
1997). CGH involves a competitive in situ hybridization of
fluorescently labelled tumour DNA and healthy control DNA to
normal metaphase chromosomes (Figure 1). Computer-assisted
fluorescence microscopy is then used to assess the intensity of
fluorochrome across each human chromosome. The differences in
tumour and control fluorescence intensity along each chromosome
on the reference metaphase spread are a reflection of the copy
number changes of corresponding sequences in the tumour DNA.
If chromosomes or chromosomal subregions are present in iden-
tical copy number within both the tumour and the normal DNA, an
equal contribution from each fluorochrome is seen. However, a
change in the fluorescent signal is seen if certain chromosomal
subregions are gained or lost in the tumour DNA (Figure 1). The
intensity of this signal is proportional to the amount of gain and
loss seen for each region in the tumour DNA (Kallioniemi et al,
1992; Forozan et al, 1997). Regions with a high level of
heterochromatin and centromeric regions are not informative with
CGH. CGH data for the p regions of acrocentric chromosomes
(e.g. 13p, 14p and 15p) must be interpreted with caution as
repetitive sequences in these regions can affect the efficiency of
competitive hybridization. With current technology, CGH has a
theoretical limit of detection for gain and loss of genetic material
of 5–10 Mb. However, gain of DNA in regions as small as 50 kb
have been described in situations where high level amplification
has occurred (Ried et al, 1997).
Initial studies with CGH were restricted to DNA prepared from
fresh or snap-frozen tumour material. More recently, technical
advances have allowed the extraction of DNA from formalin-
fixed paraffin-embedded sections through the use of degenerate
oligonucleotide primed polymerase chain reaction (DOP-PCR)
(Isola et al, 1994; Kuukasjarvi et al, 1997). The DOP-PCR
technique allows genome-wide amplification of tumour DNA
from nanogram quantities to the micrograms needed for CGH,
and has enabled retrospective analysis of genomic loss and gain
to be performed using DNA from archival material.
Although CGH analysis has been performed in a wide variety of
adult and paediatric tumours, these results have not been exten-
sively interpreted in the context of the CGH findings from other
tumour types. In this review, the results of CGH analysis in
27 tumour types are evaluated to identify regions of loss or gain
which are common to all malignancies as well as those which
are specific for a given tumour type or tumour subtype. In
addition, the degree of overall genomic instability for specific
tumour types has been assessed.
REVIEW OF THE LITERATURE
The Institute for Scientific Information (ISI) database from March
1992 to August 1998 identified 100 papers which described CGH
findings in 2210 solid tumours of 27 cancer types (Appendix).
This included common tumours (colon, breast, lung), gender-
specific tumours (ovarian, cervix, testicular, prostate), paediatric
tumours (neuroblastoma, rhabdomyosarcoma) and less common
tumours (brain, renal, uveal melanoma). For each paper, the
patterns of loss and gain in the p and q arms of each chromosome
were recorded separately. Such an approach may not always be
sufficient, as variation in subregions of the same chromosomal
arm could be masked in some cases. However, a narrower
definition for regions of gain and/or loss was not possible due to
differences in the way CGH results have been presented in the
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literature. Studies of CGH in patients with leukaemia, lymphoma
or studies with incomplete details of results for individual chromo-
somes were not included in this review. Cell line data were not
included due to the difficulty in differentiating between initial
chromosomal aberrations and those ‘acquired’ during cell culture.
The frequency of overall loss or gain for each chromosome arm
was determined by pooling the data from all tumours, from a given
tumour type and from specific tumour subtypes.
PATTERNS OF CHROMOSOMAL LOSS AND GAIN
Solid tumours
The frequency of loss or gain for each chromosome arm was
determined for all the solid tumours by pooling the data found in
the literature for 2210 tumours (Table 1). Gain of chromosomal
material was found more frequently than loss among the solid
Normal DNA Tumour DNA
Hybridization
Normal human metaphase spread
Fluorescence microscopy
Digital image analysis
Amplification in tumour
Loss in tumour
Tumour DNA vs normal DNA
Figure 1 A typical CGH experiment. Fluorescently labelled tumour DNA and reference DNA are competitively hybridized to donor human chromosomes.
Using fluorescent microscopy the level of signal from the fluorescent DNA is assessed for each chromosome. For each chromosome a profile of the level of
fluorescence is generated on CGH interpreting software. In most cases at least 10 chromosomes are assessed and an average of the fluorescence is
generated. This allows regions of loss and gain that are consistently changed to be detected for a particular tumour sample864 PH Rooney et al
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tumours (mean 4.2 gain per tumour vs 3.1 loss per tumour). A vari-
able pattern of chromosomal gain was observed, with the highest
frequency of gain found in 8q (27.7%) and 1q (25.1%) (Table 1).
This contrasts with chromosome 22p (0.3%) and 15p (0.4%)
where gain of chromosomal material was rarely observed (Table
1). The most common regions of chromosomal loss were found on
13q (16.3% of all tumours), 9p (16.1%) and 8p (15.0%) (Table 1).
Loss of chromosomal material was rarely seen on chromosome
21p (0.1%), 13p (0.4%) and 14p (0.5%). From Figure 2 it can be
seen that levels of loss and gain are not uniform across all chromo-
somal regions. Certain chromosomal regions, such as 8q, are
often gained (27.7%) but rarely lost (2.9%). Similarly, loss in
chromosome 4q was more common (13.4%) than gain (5.3%).
This pattern was not seen for all chromosomes, with loss of
13q (16.3%) only 1.8 times more common than gain (9.2%).
Patterns of nearly equal frequency of loss and gain were also
observed for chromosomes 14q (9% gain vs 8.2% loss) and
15q (7.8% gain vs 7.2% loss). However, this does not take into
account the specific region of a chromosomal arm to which the
genetic loss or gene amplification in solid tumours is mapped.
It also does not account for tumour-specific patterns of chromo-
somal gain and loss (Table 2), where the same chromosomal arm is
rarely lost and gained to an equal extent for a particular tumour
type.
Table 1 Loss and gain for each chromosomal arm when available CGH data from 2210 tumours (including 27 different solid tumour
types) were pooled
Chromosomal region Total tumour Gain (%) Chromosomal region Total tumour Loss (%)
n = 2210 n = 2210
8q + gains 616 27.7 13q – losses 363 16.3
1q + gains 558 25.1 9p – losses 357 16.1
7q + gains 513 23.1 8p – losses 333 15
7p + gains 477 21.5 10q – losses 304 13.7
17q + gains 412 18.5 3p – losses 297 13.4
3q + gains 365 16.4 4q – losses 297 13.4
20q + gains 344 15.5 6q – losses 296 13.3
5p + gains 292 13.2 17p – losses 260 11.7
12q + gains 290 13.1 18q – losses 245 11
12p + gains 277 12.5 1p – losses 226 10.2
11q + gains 252 11.3 11q – losses 218 9.8
6p + gains 246 11.1 5q – losses 206 9.1
20p + gains 223 10 10p – losses 202 9.1
19q + gains 223 10 16q – losses 196 8.8
2p + gains 214 9.6 4p – losses 188 8.5
13q + gains 205 9.2 22q – losses 184 8.3
19p + gains 203 9.1 14q – losses 183 8.2
1p + gains 201 9 9q – losses 170 7.7
14q + gains 201 9 11p – losses 167 7.5
2q + gains 198 8.9 15q – losses 161 7.2
17p + gains 179 8.1 2q – losses 153 6.8
16p + gains 176 7.9 Xp – losses 152 6.8
8p + gains 175 7.9 Xq – losses 126 5.7
15q + gains 174 7.8 21q – losses 122 5.5
5q + gains 168 7.6 Y – losses 122 5.5
6q + gains 164 7.4 18p – losses 119 5.4
9q + gains 156 7 19p – losses 112 5
18p + gains 153 6.9 17q – losses 105 4.7
16q + gains 140 6.3 3q – losses 102 4.6
18q + gains 136 6.1 12q – losses 98 4.4
22q + gains 133 6 19q – losses 96 4.3
10p + gains 131 5.9 1q – losses 89 4
Xq + gains 129 5.8 6p – losses 84 3.8
4q + gains 118 5.3 16p – losses 83 3.7
10q + gains 117 5.3 5p – losses 83 3.7
9p + gains 116 5.2 2p – losses 82 3.7
Xp + gains 115 4.7 8q – losses 64 2.9
3p + gains 104 4.7 7q – losses 56 2.5
21q + gains 101 4.5 20q – losses 53 2.4
11p + gains 97 4.4 20p – losses 53 2.4
4p + gains 95 4.3 12p – losses 52 2.3
Y + gains 55 2.5 7p – losses 50 2.3
14p + gains 24 1.1 22p – losses 36 1.6
21p + gains 22 1 15p – losses 21 0.9
13p + gains 17 0.8 14p – losses 10 0.5
15p + gains 9 0.4 13p – losses 9 0.4
22p + gains 6 0.3 21p – losses 3 0.1
Total gains 9320/2210 4.2 per tumour Total losses 6988/2210 3.1 per tumourCGH in solid tumours 865
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Specific tumour types
The frequency of chromosomal loss and gain varied between the
individual tumour types, ranging from multiple regions per tumour
(average gains: head and neck 12.2 per tumour, testicular 8.2 per
tumour; loss: liver 7.5 per tumour, prostate 4.5 per tumour) to
relatively rare events (average gains: neuroblastoma 0.5 per
tumour, Wilms’ 1.6 per tumour; loss: sarcoma 0.8 per tumour,
Wilms’ 1.3 per tumour (Table 3). The specific chromosomal
regions of loss and gain differ substantially between specific
tumour types. For example, gain in chromosome 12p occurred in
96.3% of testicular cancers and 0% of renal cancers (Table 2).
New information on chromosomal loss or gain (Table 1) can be
further specified amongst the various tumour types. For example,
gain in chromosome 8q occurred in 27.7% of all tumours evalu-
ated. However, on closer examination, frequency of 8q gain was
high in tumours of the testis (40.7%), ovary (42.8%) and
endometrium (45.5%), but was rarely found in renal tumours
(1.3%) and neuroblastoma (3.0%). There is no chromosomal arm
which demonstrated a consistent pattern of gain for all tumour
types. Similar findings were demonstrated for chromosomal loss.
For instance, 9p was lost in 16.1% of all tumours, but varied from
a high frequency event (cutaneous melanoma 58.2%, pancreas
50.1%, brain 36.3%) to low (colon 7.5%, gastric cancer 7%)
depending on the tumour type (Table 2).
Specific tumour subtypes
For several tumours, CGH analysis was available for multiple
histological subtypes (Table 4). This allowed assessment of both
the frequency at which loss and gain occurred and the extent to
which each specific chromosomal arm is involved for each
subtype.
Colon
Information on genomic alterations in colon cancer was available
for low- and high-grade adenoma, primary carcinomas, liver
metastases, and also carcinomas for which replication error repair
status was known (Table 4). Ried et al (1995) found the frequency
and degree of genetic aberrations increases with progression from
low-grade adenoma through high-grade adenoma to carcinoma
(Table 4). For example, gain in chromosome 7p was 7.1% in
low-grade adenoma, 33.3% in high-grade adenoma and 50%
in carcinoma. Similarly, gain in chromosome 20q was not detected
in low-grade adenoma, but was at 33.3% and 75% in high-grade
adenoma and carcinoma respectively. The frequency of alterations
also increased with tumour progression: 3/47 chromosomal arms
in low-grade adenoma, 21/47 high-grade adenoma, 32/47 carci-
nomas. A separate study by Paredes-Zaglul et al (1998) comparing
primary carcinomas and liver metastases from patients with
colorectal cancer found that the frequency of alteration remained
constant at ~ 35/47 chromosomal arms between these two stages.
However, a change was noted in the extent to which these arms
were involved. The most obvious change being the increase in loss
of genetic material between primary tumour and liver metastases.
For example, loss at 8p was 30% in primary carcinomas compared
with 80% in metastases. Similarly, loss of 18q was found in 50%
of primary cases, but 90% of liver metastases. Changes in gain did
not always follow the same pattern seen for loss. An increase in
genetic instability was seen for some chromosomal regions in the
transition from primary to metastases (e.g. 13q was gained in 30%
of primary tumours compared with 50% in metastases). However,
this was not the case for other regions, such as 12q, which was
gained in 20% of primary carcinomas, but was normal in liver
metastases. A difference in genetic instability was also seen
between tumours with intact mismatch repair genes compared to
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Figure 2 The overall number of gains and losses detected in 2210 solid tumours from 27 different tumour types866 PH Rooney et al
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those with deficient repair ability (Table 4). As expected, the
tumours lacking repair function had a higher frequency of insta-
bility. For example, gain of 7p and 7q was seen in 33% of tumours
with non-functioning repair genes, while these aberrations were
absent in tumours with intact DNA repair phenotype. Although a
relationship between genomic instability and both tumour progres-
sion and repair deficiency had been previously suggested, CGH
has provided strong data to support this hypothesis in tumour
specimens.
Ovary
Several studies have been published assessing the genomes of
ovarian cancer cases. The available data were split into ovarian
cancers derived from the epithelia and those derived from germ
cells. Cancers of the epithelia were then further subdivided into
sporadic and hereditary cases. The hereditary cases were defined
as such based on BRCA1 and BRCA2 status. It is appreciated that
some papers did not assess their cases for BRCA1 and BRCA2
and that a small percentage of the sporadic cases may have altered
BRCA genes. Overall, however, this division of ovarian tumours
has yielded some useful observations. Firstly, it was found that the
frequency of genetic aberrations was greatest in the sporadic cases
at 41/47 chromosomal arms, compared with 33/47 in hereditary
cases and 30/47 in the germ cell tumours. The greatest level of
concordance was at 1q and 8q where gains occurred at approxi-
mately 30% and 50%, respectively, in all three tumour types. Both
hereditary and sporadic cases had a high degree of gain at 3q
(40.6% in sporadic and 50% in inherited cases). This is in contrast
to the same region being gained in only 5.3% of germ cell
tumours. However, all three tumour subtypes are likely to have
some common genetic origin based on the observation that regions
such as 1q and 8q are gained to an equal extent in all ovarian
cancer types so far studied by CGH.
Prostate
The data on prostate cancer allowed comparison of CGH results in
patient cohorts with primary resected carcinomas or tumours that
recurred after hormone therapy. It has been speculated that further
genetic damage allows a subclone of tumour cells to acquire resis-
tance to chemotherapy and such studies can test this hypothesis.
Very little change in the frequency of genetic aberration between
primary carcinoma and recurrent carcinoma was seen (39/47 in
primary vs 42/47 in recurrent). However, differences were seen in
the degree of genetic aberration when specific chromosomal
regions were considered. For example, gain in chromosome 8q
was seen in 25.9% primary carcinomas compared with 73.9% in
recurrent cases. Similarly, 19p was lost in 3.7% of primary
tumours and 34.8% in recurrent cases. Gain in the region
containing the androgen receptor gene, Xp, increased from 7.4%
in primary tumour to 28.3% in patients with recurrent disease.
This is consistent with androgen receptor gene amplification as a
mechanism of resistance to hormone therapy. However, this was
not always the case with some regions of the genome only slightly
changed in the degree of the aberration between primary and
recurrent. For example, 3p was lost in 1.9% of primary tumours
and 4.3% in recurrent cases. Generally, the data support the
hypothesis that increased tumour aggression is the phenotype of a
more unstable genome.
Table 3 The number of altered chromosomal arms observed among the different tumour types
Cancer type Gains/tumour Losses/tumour Total instability
(loss + gain) per tumour
Gastric carcinoma 365\68 5.4 128\68 1.9 7.3
Gastrointestinal stromal 52\32 1.6 71\32 2.2 3.8
Head and neck 588\47 12.5 245\47 5.2 17.7
Pancreatic 231\51 4.5 188\51 3.7 8.2
Colorectal 204\80 2.6 190\80 2.4 5
Prostate 312\100 3.1 447\100 4.5 7.6
Testicular 337\41 8.2 171\41 4.2 12.4
Breast 752\187 4 549\187 2.9 6.9
Ovarian 1136\203 5.6 499\203 2.5 8.1
Endometrial 186\33 5.6 50\33 1.5 7.1
Cervical 163\30 5.4 124\30 4.1 9.5
Cutaneous melanoma 203\67 3 227\67 3.4 6.4
Merkel cell carcinoma 23\3 8 13\3 4.3 12.3
Uveal melanoma 23\11 2.1 27\11 2.5 4.6
Renal 346\151 2.3 530\151 3.5 5.8
Bladder 222\96 2.3 278\96 2.9 5.2
Wilms’ 89\54 1.6 71\54 1.3 2.9
Connective tissue sarcoma 530\193 2.7 154\193 0.8 3.5
Rhabdomyosarcoma 158\24 6.6 61\24 2.5 9.1
Lung 845\142 6 599\142 4.2 10.2
Liver 201\43 4.7 322\43 7.5 12.2
Neuroblastoma 56\118 0.5 439\118 3.7 4.2
Brain 1152\325 3.5 1076\325 3.3 6.8
Gastro-oesophageal 100\15 6.7 50\15 3.3 10
Parathyroid 38\53 7.2 121\53 2.3 9.5
Pituitary 92\23 4 22\53 4.2 8.2
Neuroendocrine* 162\20 8.1 57\20 2.9 11
*Sporadic neuroendocrine tumours of the digestive system.868 PH Rooney et al
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Connective tissue tumours
CGH data were available for several tumour types (liposarcoma,
alveolar soft part sarcoma, osteosarcoma, Ewing’s, rhabdomyosar-
coma and osteochondroma). Unlike the other subtypes discussed
(colon, ovary and prostate), tumours of the connective tissue are
found in many different sites throughout the body. Considering the
frequency of genetic aberration, the widest range of variation
between subtypes among any tumour type in the literature is
observed in the sarcomas. At one end of the spectrum a study on
osteochondromas reports no genetic aberrations in 15 cases of this
benign tumour type (Larramendy et al, 1997). Such a paper is
unique in the CGH literature as all other investigations report some
genomic change detectable by CGH. The alveolar soft part- and
osteosarcomas show low to moderate frequency of genetic aberra-
tion at 14 and 19 out of 47 chromosomal arms respectively. While
the other subtypes showed moderate to high numbers of arms
involved (range 28–38 of 47). Another unique observation in the
CGH literature was seen in an osteosarcoma study where only gain
of genetic material was detected (Forus et al, 1995). Caution must
be exercised when interpreting such results as it is unlikely that
this cancer is the exception where no loss of genetic material is
required for its development. More likely any loss, such as that
of a tumour suppressor gene, is below detection by CGH.
Rhabdomyosarcomas are further subdivided histologically into
alveolar and embryonal types. Generally, a higher degree of gain
and loss is seen in the embryonal rhabdomyosarcoma compared
Table 4 Patterns of loss(2) and gain in specific tumour subtypes shown as the percentage of tumours with involvement for selected
chromosomes
Tumour type Colon†
lga Hga Carcinoma Min– Min+ Primary Metastases
CR n=14 n=12 n=16 n=6 n=12 n=10 n=10
7p 7.1 33.3 50 0 33.3 10 10
7q 0 25 31.3 0 33.3 30 30
8p 0 0 0 0 0 10&–30 10&–80
12q 0 8.3 6.3 0 0 20 0
13q 0 8.3 50 –16.7 41.7 30&–10 50
18q 0 –16.7 –37.5 0 –25 –50 –90
20q 0 33.3 75 0 25 50 40
Involved arms 3\47 21\47 32\47 3\47 22\47 34\47 35\47
Tumour type Ovary
Sporadic* Inherited OGCT
CR n=148 n=20 n=19
1q 34.8&–0.7 30 31.6
2q 18.1&–1.4 50&–5 0
3q 40.6 50 5.3&–5.3
8q 52.9&–0.7 55 42.1
21q 5.8&–7.2 0 47.4
Involved arms 41\47 33\47 30\47
Tumour type Prostate
Primary Recurrent
CR n=54 n=46
3p –1.9 4.3&–4.3
7p 3.7 34.8&–2.2
7q 13&–1.9 34.8&–2.2
8p –46.5 8.7&–60.9
8q 25.9 73.9
19p 7.4&–3.7 –34.8
Xp 7.4&–1.9 28.3&–8.7
Xq 14.8 15.2&–6.5
Involved arms 39\47 42\47
Tumour type Sarcoma
Osteosarcoma RMS-E RMS-A Liposarcoma ASPS Ewing’s
CR n=14 n=10 n=14 n=14 n=13 n=20
2p 0 50 50 0 0 5
6p 28.6 0 7.1 0 0 10
2q 7.1 60 –14.3 14.3 0 5
13q 14.3 60&–10 35.7&–7.1 7.1&–21.4 0 5
16q 0 2&–30 7.1&–7.1 7.1 –7.7 5&–5
Involved arms 19\47 38\47 35\47 38\47 14\47 28\47
In several tumour subtypes both loss and gain were observed on the same chromosomal arm. Variation in the number of chromosomal
arms involved in genetic instability was also observed between subtypes. *Contains tumours which were not evaluated for BRCA1 and
BRCA2 status. † represents data from three separate studies evaluating tumour progression, microsatellite instability and metastasis
respectively. CR = chromosomal region; Iga = low-grade adenoma; Hga = high-grade adenoma; OGCT = ovarian germ cell tumours;
MIN+ = without microsatellite instability; MIN– = with microsatellite instability; RMS-E = rhabdomyosarcoma embryonal; RMS-A =
rhabdomyosarcoma alveolar; ASPS = alveolar soft part sarcomawith alveolar rhabdomyosarcoma (Weber-Hall et al, 1996). For
example, a sub-chromosomal region of 13q is gained in 60% and
lost in 10% of embryoneal, while the same region is gained in
35.7% and lost in 7.1% of alveolar, rhabdomyosarcomas. The
exception is 2p, which is lost in 50% of cases in both subtypes.
Comparing both subtypes of rhabdomyosarcoma with other
sarcomas it is observed that a gain of 2q is not present in a high
proportion in all sarcomas. In fact no change in 2q is detected in
liposarcoma or alveolar soft part sarcoma and gain in Ewing’s
sarcoma is detected in less than 10% of all cases. This pattern of a
certain chromosomal region commonly occurring in a specific
subtype, but not in any other, continues for many chromosomal
regions, suggesting that sarcomas are very distinct in terms of their
genetic origin, with each subtype having its own marker chromo-
somal aberrations. This may be due to the variation in tissue type
in which these tumours arise. No single chromosomal aberration
was found to be present in a high proportion of all sarcomas.
PATTERNS OF GENOMIC IMBALANCE OR
INSTABILITY IN SOLID TUMOURS
The degree of genomic imbalance detectable by CGH differs
significantly between the various solid tumours (Table 3).
Chromosomal gain varied from 0.5 to 12.5 chromosome arms per
tumour with a median of 4.5, while loss varied from 0.8 to 7.5
chromosomal arms per tumour with a median of 3.3. Total insta-
bility (chromosomal loss + chromosomal gain per number of
tumours) was highest in head and neck tumours (17.7 lesions per
tumour) and testicular (12.4 lesions per tumour) and lowest in
Wilms’ (2.9 lesions per tumour) and sarcoma (3.5 lesions per
tumour) tumours. These frequencies represent an overall value for
each specific tumour type, as information on the chromosomal
alterations found within an individual tumour was not available in
most literature reports of CGH in human solid tumours. Difference
in the degree of loss or gain was also observed between the various
solid tumours (Table 3). For example, chromosomal gain was
observed more frequently than loss in the sarcomas and endome-
trial tumours, while loss was more frequently observed for renal
and liver tumours. It is unknown whether these patterns represent
coincidental changes from generalized genomic instability or
suggest that some cancers are more likely to be influenced by the
loss of tumour suppressor genes (genomic loss), while others are
more frequently influenced by oncogene over expression (genomic
gain). In addition, several studies have identified an association
between the acquisition of genetic aberrations and patient survival
(Iwabuchi et al, 1995; Tanner et al, 1995). However, there are
discrepancies in this association found in Table 3, and any correla-
tions between biological markers and patient survival need to be
interpreted cautiously in the context of modern therapy.
COMPARISON WITH SOLID TUMOUR
KARYOTYPE ANALYSIS
Classical karyotyping of metaphase chromosomes has been
successfully performed for some solid tumours. A recent review
reported the frequencies and distribution of chromosomal imbal-
ances detected in 3185 solid tumours from 11 tumour types using
chromosomal banding (Merkel et al, 1997). Overall, deletions were
more common than gains in this analysis. Our review has found the
opposite, with gains more commonly detected by CGH than losses.
This difference may reflect the difficulties with using tumour kary-
otyping to identify the chromosomal changes that have occurred in
tumours with highly complex rearrangements and will be influ-
enced to some extent by amplified segments being hidden among
unidentified marker chromosomes. CGH should be more sensitive
for the detection of the presence of gains than losses and therefore
the discrepancies with the above study are likely to reflect technical
limitations of the two methods. By restricting analysis to common
alterations (i.e. the gain or loss was detected in at least 15% of the
tumours studied for that particular tumour type), the classical kary-
otyping studies described fewer regions of gain and loss than CGH
for every tumour type evaluated. CGH appeared to identify the
same alterations described using the karyotyping approach (with
the exception of balanced translocations which are not detectable
by CGH), but also observed additional regions of loss or gain. For
example, only two regions of gain were detected in ovarian carci-
noma by traditional cytogenetic analysis compared with 26 regions
of gain seen by CGH. However, there have been too few studies of
solid tumour cytogenetics using both CGH and chromosome
banding for any firm conclusions regarding concordance between
the two techniques. Nevertheless, the accumulating body of
evidence in the literature suggests that CGH is more sensitive than
other current technologies available for global assessment of loss
and/or gain in solid tumour genomes.
CONCLUSION
From this review, it is apparent that no specific chromosomal
imbalances are found in all cancers, with the most frequently
identified regions of gain or loss occurring in 27.7% and 16.3% of
tumours respectively. This reflects the heterogeneity in genomic
alterations identified in different tumour types. In addition, much
variation within tumour subtypes was observed.
The development of CGH has provided the technology to iden-
tify many new areas of genomic alteration which were not previ-
ously recognized to be altered in tumorigenesis. This has now
expanded the number of areas of the genome for which more
detailed molecular study is required to give a clearer more
complete understanding of cancer biology.
Other areas where CGH could potentially make a significant
contribution include its application in tumour diagnosis, as a prog-
nostic tool, or for investigations into chemoresistance. The ability
to assess the entire genome in a single experiment makes this tech-
nique potentially useful as an adjunct to routine histopathology.
Several studies have established the feasibility of using CGH to
detect genomic regions involved in the acquisition of resistance in
human cancer cell lines and have detected novel regions of the
genome not previously recognized to be involved in drug resis-
tance (du Manoir et al, 1997; Wasenius et al, 1997; Leyland-Jones
et al, 1998; Rooney et al, 1998). This provides the impetus to apply
CGH to human tumour specimens in the context of modern drug
therapy to assess its role in optimizing patient treatment.
ACKNOWLEDGEMENTS
Many thanks to Dr Lars-Peter Erwig for translation of a German
paper. This work was supported in part by a University of
Aberdeen Research Consortium studentship, a University of
Aberdeen Equipment Award and an Aberdeen Royal Infirmary
endowment grant.
CGH in solid tumours 869
British Journal of Cancer (1999) 80(5/6), 862–873 © Cancer Research Campaign 1999870 PH Rooney et al
British Journal of Cancer (1999) 80(5/6), 862–873 © Cancer Research Campaign 1999
REFERENCES
Dowsett M, Daffada A, Chan CMW and Johnston SRD (1997) Oestrogen receptor
mutants and variants in breast cancer. Eur J Cancer 33: 1177–1183
du Manoir S, Speicher MR, Joos S, Schrock E, Popp S, Döhner H, Kovacs G,
Robert-Nicoud M, Lichter P and Cremer T (1993) Detection of complete and
partial chromosome gains and losses by comparative genomic in situ
hybridization. Hum Genet 90: 590–610
du Manoir S, Myers TG, Paull KD, Bell DW, Liu ZM, Feder MM, Weinstein JN,
Sonoda G and Testa JR (1997) Analysis by CGH of the tumor cell lines of NCI
anticancer drug discovery screen. Proc Am Assoc Cancer Res 38: 606
Forozan F, Karhu R, Kononen J, Kallioniemi A and Kallioniemi O-P (1997) Genome
screening by comparative genomic hybridisation. TIGS 13: 405–409
Forus A, Olde Weghuis D, Smeets D, Fodstad Ø, Myklebost O and van Kessel AG
(1995) Comparative genomic hybridization analysis of human sarcomas: II.
Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes
Chromosomes Cancer 14: 15–21
Isola J, DeVries S, Chu L, Ghazvini S and Waldman F (1994) Analysis of changes in
DNA sequence copy number by comparative genomic hybridization in archival
paraffin-embedded tumor samples. Am J Pathol 145: 1301–1308
Iwabuchi H, Sakamoto M, Sakunaga H, Ma Y-Y, Carcangiu ML, Pinkel D, Yang-
Feng TL and Gray JW (1995) Genetic analysis of benign, low-grade, and high-
grade ovarian tumors. Cancer Res 55: 6172–6180
Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F and
Pinkel D (1992) Comparative genomic hybridisation for the genetic analysis of
solid tumours. Science 258: 818–821
Kallioniemi O-P, Kallioniemi A, Sudar D, Rutovitz D, Gray JW, Waldman F and
Pinkel D (1993) Comparative genomic hybridization: a rapid new method for
detecting and mapping DNA amplification in tumors. Semin Cancer Biol 4:
41–46
Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Visakorpi T and Isola J (1997)
Optimizing DOP-PCR for universal amplification of small DNA samples in
comparative genomic hybridization. Genes Chromosomes Cancer 18: 94–101
Larramendy ML, Tarkkanen M, Blomqvist C, Virolainen M, Wiklund T,
AskoSeljavaara S, Elomaa I and Knuutila S (1997) Comparative genomic
hybridization of malignant fibrous histiocytoma reveals a novel prognostic
marker. Am J Pathol 151: 1153–1161
Levitzki A and Gazit A (1995) Tyrosine kinase inhibition: an approach to drug
development. Science 267: 1782
Leyland-Jones B, Bradshaw TD, Skelton L, Kelland LR, Fisher LM and Hiorns LR
(1998) Genomic alterations associated with acquired resistance to novel
antitumor agents. Proc Am Assoc Cancer Res 39: 658
Mertens F, Johansson B, Höglund M and Mitelman F (1997) Chromosomal
imbalance maps of malignant solid tumors: a cytogenetic survey of 3185
neoplasms. Cancer Res 57: 2765–2780
Paredes-Zaglul A, Kang JJ, Essig YP, Mao WG, Irby R, Wloch M and Yeatman TJ
(1998) Analysis of colorectal cancer by comparative genomic hybridization:
evidence for induction of the metastatic phenotype by loss of tumor suppressor
genes. Clin Cancer Res 4: 879–886
Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E, Heselmeyer K, duManoir S
and Auer G (1996) Comparative genomic hybridization reveals a specific
pattern of chromosomal gains and losses during the genesis of colorectal
tumors. Genes Chromosomes Cancer 15: 234–245
Ried T, Liyanage M, du Manoir S, Heselmeyer K, Auer G, Macville M and Schröck
E (1997) Tumor cytogenetics revisited: comparative genomic hybridisation and
spectral karyotyping. J Mol Med 75: 801–814
Rooney PH, Marsh S, Stevenson DAJ, Johnston PG, Haites NE, Cassidy J and
McLeod HL (1998) Genome wide assessment in cell lines resistant to
thymidylate synthase inhibitors. Cancer Res 58: 5042–5045
Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray JW,
Kallioniemi O-P and Isola J (1995) Amplification of chromosomal region
20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1:
1455–1461
Telenius H, Pelmear AH, Tunnacliffe A, Carter NP, Behmel A, Ferguson-Smith MA,
Nordenskjold M, Pfragner R and Ponder BAJ (1992) Cytogenetic analysis by
chromosome painting using DOP-PCR amplified flow-sorted chromosomes.
Genes Chromosomes Cancer 4: 257–263
Vogel F (1979) Genetics of retinoblastoma. Hum Genet 52: 1–54
Waldman FM, Sauter G, Sudar D and Thompson CT (1996) Molecular cytometry of
cancer. Hum Pathol 27: 441–449
Wasenius VM, Jekunen A, Monni O, Joensuu H, Aebi S, Howell SB and Knuutila S
(1997) Comparative genomic hybridization analysis of chromosomal changes
occurring during development of acquired resistance to cisplatin in human
ovarian carcinoma cells. Genes Chromosomes Cancer 18: 286–291
Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-
Jones K and Shipley J (1996) Gains, losses, and amplification of genomic
material in rhabdomyosarcoma analyzed by comparative genomic
hybridization. Cancer Res 56: 3320–3224
APPENDIX
Bladder
Kallioniemi A, Kallioniemi O-P, Citro G, Sauter G, DeVries S, Kerschmann R,
Caroll P and Waldman F (1995) Identification of gains and losses of DNA
sequences in primary bladder cancer by comparative genomic hybridization.
Genes Chromosomes Cancer 12: 213–219
Richter J, Jiang F, Görög J-P, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch
MJ and Sauter G (1997) Marked genetic differences between stage pTa and
stage pT1 papillary bladder cancer detected by comparative genomic
hybridization. Cancer Res 57: 2860–2864
Voorter C, Joos S, Bringuier P-P, Vallinga M, Poddighe P, Schalken J, du Manoir S,
Ramaekers F, Lichter P and Hopman A (1995) Detection of chromosomal
imbalances in transitional cell carcinoma of the bladder by comparative
genomic hybridization. Am J Pathol 146: 1341–1354
Brain
Carlson KM, Bruder C, Nörderskjord M and Dumanski JP (1997) 1p and 3p
deletions in meningiomas without detectable aberrations of chromosome 22
identified by comparative genomic hybridisation. Genes Chromosomes Cancer
20: 419–424
Khan J, Parsa NZ, Harada T, Meltzer PS and Carter NP (1998) Detection of gains
and losses in 18 meningiomas by comparative genomic hybridization. Cancer
Genet Cytogenet 103: 95–100
Kim DH, Mohapatra G, Bollen A, Waldman FM and Feuerstein BG (1995)
Chromosomal abnormalities in glioblastoma-multiforme tumors and glioma
cell-lines detected by comparative genomic hybridization. Int J Cancer 60:
812–819
Mohapatra G, Bollen AW, Kim DH, Lamborn K, Moore DH, Prados MD and
Feuerstein BG (1998) Genetic analysis of glioblastoma multiforme provides
evidence for subgroups within the grade. Genes Chromosomes Cancer 21:
195–206
Nishizaki T, Ozaki S, Harada K, Ito H, Arai H, Beppu T and Sasaki K (1998)
Investigation of genetic alterations associated with the grade of astrocytic
tumor by comparative genomic hybridization. Genes Chromosomes Cancer 21:
340–346
Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST,
Valentine MB, Behm FG, Li H, Heideman RL, Kun LE and Shapiro DN (1997)
Extensive genomic abnormalities in childhood medulloblastoma by
comparative genomic hybridization. Cancer Res 57: 4042–4047
Sallinen SL, Sallinen P, Haapasalo H, Kononen J, Karhu R, Helen P and Isola J
(1997) Accumulation of genetic changes is associated with poor prognosis in
grade II astrocytomas. Am J Pathol 151: 1799–1807
Schlegel J, Scherthan H, Arens N, Stumm G and Kiessling M (1996) Detection of
complex genetic alterations in human glioblastoma multiforme using
comparative genomic hybridization. J Neuropath Exp Neuro 55: 81–87
Schröck E, Thiel G, Lozanova T, du Manoir S, Meffert M-C, Jauch A, Speicher MR,
Nürnberg P, Vogel S, Jänisch W, Doris-Keller H, Ried T, Witkowski R and
Cremer T (1994) Comparative genomic hybridization of human malignant
gliomas reveals multiple amplification sites and nonrandom chromosomal
gains and losses. Am J Pathol 144: 1203–1218
Schröck E, Blume C, Meffert M-C, du Manior S, Bersch W, Kiessling M,
Lozanowa T, Thiel G, Witkowski R, Ried T and Cremer T (1996)
Recurrent gain of chromosome arm 7q in low-grade astrocytic tumors studied
by comparative genomic hybridization. Genes Chromosomes Cancer 15:
199–205
Weber RG, Sommer C, Albert FK, Kiessling M and Cremer T (1996) Clinically
distinct subgroups of glioblastoma multiforme studied by comparative genomic
hybridisation. Lab Invest 74: 108–119
Weber RG, Sabel M, Reifenberger J, Sommer C, Oberstrab J, Reifenberger G,
Kiessling M and Cremer T (1996) Characterization of genomic alterations
associated with glioma progression by comparative genomic hybridization.
Oncogene 13: 983–994CGH in solid tumours 871
British Journal of Cancer (1999) 80(5/6), 862–873 © Cancer Research Campaign 1999
Breast
Courjal F and Theillet C (1997) comparative genomic hybridization analysis of
breast tumors with predetermined profiles of DNA amplification. Cancer Res
57: 4368–4377
Guan X-Y, Xu J, Anzick SL, Shang H, Trent JM and Meltzer PS (1996) Hybrid
selection of transcribed sequences from microdissected DNA: isolation of
genes within an amplified region at 20q11-q13.2 in breast cancer. Cancer Res
56: 3446–3450
Isola J, Kallioniemi O-P, Chu LW, Fuqua SAW, Hilsenbeck SG, Osborne K and
Waldman FM (1995) Genetic aberrations detected by comparative genomic
hybridization predict outcome in node-negative breast cancer. Am J Pathol 147:
905–911
Kuukasjärvi T, Tanner M, Pennanen S, Karhu R, Kallioniemi OP and Isola J (1997)
Genetic changes in intraductal breast cancer detected by comparative genomic
hybridization. Am J Pathol 150: 1465–1471
Lu Y-J, Birdsall S, Osin P, Gusterson B and Shipley J (1997) Phyllodes tumors of the
breast analyzed by comparative genomic hybridization and association of
increased 1q copy number with stromal overgrowth and recurrence. Genes
Chromosomes Cancer 20: 275–281
Nishizaki T, DeVries S, Chew K, Goodson WH III, Ljung B-M, Thor A and
Waldman FM (1997) Genetic alterations in primary breast cancers and their
metastases: direct comparison using modified comparative genomic
hybridization. Genes Chromosomes Cancer 19: 267–272
Ried T, Just KE, Holtgreve-Grez H, du Manoir S, Speicher MR, Schröck E, Latham
C, Blegen H, Zetterberg A, Cremer T and Auer G (1995) Comparative genomic
hybridization of formalin-fixed, paraffin-embedded breast tumors reveals
different patterns of chromosomal gains and losses in fibroadenomas and
diploid and aneuploid carcinomas. Cancer Res 55: 5414–5423
Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, Kowbel D,
Shadravan F, Hintz M, Kuo W-L, Waldman FM, Isola J, Gray JW and Kallioniemi
O-P (1994) Increased copy number at 20q13 in breast cancer: defining the critical
region and exclusion of candidate genes. Cancer Res 54: 4257–4260
Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray JW,
Kallioniemi O-P and Isola J (1995) Amplification of chromosomal region
20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1:
1455–1461
Tanner MM, Karhu RA, Nupponen NN, Borg A, Baldetorp B, Pejovic T, Ferno M,
Killander D and Isola J (1998) Genetic aberrations in hypodiploid breast
cancer: frequent loss of chromosome 4 and amplification of Cyclin D1
oncogene. Am J Pathol 153: 191–199
Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J and Kallioniemi OP
(1998) Molecular cytogenetics of primary breast cancer by CGH. Genes
Chromosomes Cancer 21: 177–184
Cervix
Heselmeyer K, Macville M, Schröck Blegen H, Hellström A-C, Shah K, Auer G and
Ried T (1997) Advanced-stage cervical carcinomas are defined by a recurrent
pattern of chromosomal aberrations revealing high genetic instability and a
consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 19: 233–240
Colon
Nakao K, Shibusawa M, Tsunoda A, Yoshizawa H, Murakami M, Kusano M, Uesugi
N and Sasaki K (1998) Genetic changes in primary colorectal cancer by
comparative genomic hybridization. Surg Today-Jn J Surg 28: 567–569
Paredes-Zaglul A, Kang JJ, Essig YP, Mao WG, Irby R, Wloch M and Yeatman TJ
(1998) Analysis of colorectal cancer by comparative genomic hybridization:
evidence for induction of the metastatic phenotype by loss of tumor suppressor
genes. Clin Cancer Res 4: 879–886
Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E, Heselmeyer K, duManoir S
and Auer G (1996) Comparative genomic hybridization reveals a specific
pattern of chromosomal gains and losses during the genesis of colorectal
tumors. Genes Chromosomes Cancer 15: 234–245
Schlegel J, Stumm G, Scherthan H, Bocker T, Zirngibl H, Rüschoff J and Hofstädter
F (1995) Comparative genomic in situ hybridization of colon carcinomas with
replication error. Cancer Res 55: 6002–6005
Cutaneous melanoma
Bastian BC, Leboit PE, Hamm H, Brocker EB and Pinkel D (1998) Chromosomal
gains and losses in primary cutaneous melanomas detected by comparative
genomic hybridization. Cancer Res 58: 2170–2175
Wiltshire RN, Duray P, Bittner ML, Visakorpi T, Meltzer PS, Tuthill RJ, Liotta LA
and Trent JM (1995) Direct visualization of the clonal progression of primary
cutaneous melanoma: application of tissue microdissection and comparative
genomic hybridization. Cancer Res 55: 3954–3957
Endometrium
Pere H, Tapper J, Wahlstrom T, Knuutila S and Butzow R (1998) Distinct
chromosomal imbalances in uterine serous and endometrioid carcinomas.
Cancer Res 58: 892–895
Sonoda G, du Manoir S, Godwin AK, Bell DW, Liu Z, Hogan M, Yakushiji M and
Testa JR (1997) Detection of DNA gains and losses in primary endometrial
carcinomas by comparative genomic hybridization. Genes Chromosomes
Cancer 18: 115–125
Gastroesophageal
Moskaluk CA, Hu J and Perlman EJ (1998) Comparative genomic hybridization of
esophageal and gastroesophageal adenocarcinomas shows consensus areas of
DNA gain and loss. Genes Chromosomes Cancer 22: 305–311
Gastrointestinal
El-Rifai W, Sarlomo-Rikala M, Miettinen M, Knuutila S and Andersson LC (1996)
DNA copy number losses in chromosome 14: an early change in
gastrointestinal stromal tumors. Cancer Res 56: 3230–3233
Gastric carcinoma
Koizumi Y, Tanaka S-I, Mou R, Koganei H, Kokawa A, Kitamura R, Yamauchi H,
Ookubo K, Saito T, Tominaga S, Matsumura K, Shimada H, Tsuchida N and
Sekihara H (1997) Changes in DNA copy number in primary gastric
carcinomas by comparative genomic hybridization. Clin Cancer Res 3:
1067–1076
Kokkola A, Monni O, Puolakkainen P, Larramendy ML, Victorzon M, Nordling S,
Haapiainen R, Kivilaakso E and Knuutila S (1997) 17q12–21 amplicon, a novel
recurrent genetic change in intestinal type of gastric carcinoma: a comparative
genomic hybridization study. Genes Chromosomes Cancer 20: 38–43
Head and neck
Speicher MR, Howe C, Crotty P, du Manoir S, Costa J and Ward DC (1995)
Comparative genomic hybridization detects novel deletions and
amplifications in head and neck squamous cell carcinomas. Cancer Res
55: 1010–1013
Weber RG, Scheer M, Born IA, Joos S, Cobbers JL, Hofele C, Reifenberger G,
Zoller JE and Lichter P (1998) Recurrent chromosomal imbalances detected in
biopsy material from oral premalignant and malignant lesions by combined
tissue microdissection, universal DNA amplification, and comparative genomic
hybridization. Am J Pathol 153: 295–303
Wolff E, Girod S, Liehr T, Vorderwulbecke U, Ries J, Steininger H and Gebhart E
(1998) Oral squamous cell carcinomas are characterized by a rather uniform
pattern of genomic imbalances detected by comparative genomic hybridisation.
Oral Oncol 34: 186–190
Liver
Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A and Dejean A
(1997) Recurrent chromosomal abnormalities in hepatocellular carcinoma
detected by comparative genomic hybridization. Genes Chromosomes Cancer
18: 59–65
Lung
Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E and Testa JR
(1997) Comparative genomic hybridization analysis detects frequent, often
high-level overrepresentation of DNA sequences at 3q, 5p, 7p and 8q in human
non-small-cell lung carcinomas. Cancer Res 57: 2116–2120
Björkqvist A-M, Tammilehto L, Anttila S, Mattson K and Knuutila S (1997)
Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q
detected by comparative genomic hybridization in malignant mesothelioma.
Br J Cancer 75: 523–527Björkqvist A-M, Tammilehto L, Nording S, Nurminen M, Anttila S, Mattson K and
Knuutila S (1998a) Comparison of DNA copy number changes in malignant
mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung.
Br J Cancer 77: 260–269
Björkqvist A-M, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Tammilehto L,
Mattson K, Vainio H and Knuutila S (1998b) DNA gains in 3q occur frequently
in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes
Chromosomes Cancer 22: 79–82
Kivipensas P, Bjorkqvist A-M, Karhu R, Pelin K, Linnainmaa K, Tammilehto L,
Mattson K, Kallioniemi O-P and Knuutila S (1996) Gains and losses of DNA
sequences in malignant mesothelioma by comparative genomic hybridization.
Cancer Genet Cytogenet 89: 7–13
Petersen I, Langreck H, Wolf G, Schwendel A, Psille P, Vogt P, Reichel MB, Ried T
and Dietel M (1997a) Small-cell lung cancer is characterized by a high
incidence of deletions on chromosomes 3p, 4p, 5q, 10q, 13q and 17p. Br J
Cancer 75: 79–86
Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, Schwendel A, Langreck H,
Gellert K, Reichel M, Just K, duManoir S, Cremer T, Dietel M and Ried T
(1997b) Patterns of chromosomal imbalances in adenocarcinoma and
squamous cell carcinoma of the lung. Cancer Res 57: 2331–2335
Ried T, Petersen I, Holtgreve-Grez H, Speicher MR, Schröck, du Manoir S and
Cremer T (1994) Mapping of multiple DNA gains and losses in primary small-
cell lung carcinomas by comparative genomic hybridization. Cancer Res 54:
1801–1806
Merkel cell carcinoma
Härle M, Arens N, Moll I, Back W, Schulz T and Scherthan H (1996) Comparative
genomic hybridization (CGH) discloses chromosomal and subchromosomal
copy number changes in Merkel cell carcinomas. J Cutan Pathol 23: 391–397
Neuroblastoma
Altura RA, Maris JM, Li H, Boyett JM, Brodeur GM and Look AT (1997) Novel
regions of chromosomal loss in familial neuroblastoma by comparative
genomic hybridization. Genes Chromosomes Cancer 19: 176–184
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Bocker W and
Storkel S (1996) Synopsis of unbalanced chromosomal-aberrations in
neuroblastoma by comparative genomic hybridization. Pathologe 17: 368–373
Lastowska M, Cotterill S, Pearson AJ, Roberts P, McGuckin A, Lewis I and Bown N
(1997) Gain of chromosome arm 17q predicts unfavourable outcome in
neuroblastoma patients. Eur J Cancer 33: 1627–1633
Lastowska M, Nacheva E, McGuckin A, Curtis A, Grace C, Pearson A and Brown N
(1997) Comparative genomic hybridization study of primary neuroblastoma
tumors. Genes Chromosomes Cancer 18: 162–169
Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC and Feuerstein BG
(1997) Gain of chromosome 17 is the most frequent abnormality detected in
neuroblastoma by comparative genomic hybridization. Am J Pathol 150: 81–89
Schütz BR, Scheurlen W, Krauss J, du Manoir S, Joos S, Bentz M and Lichter P
(1996) Mapping of chromosomal gains and losses in primitive neuroectodermal
tumors by comparative genomic hybridization. Genes Chromosomes Cancer
16: 196–203
Szymas J, Wolf G, Kowalczyk D, Nowak S and Petersen I (1997) Olfactory
neuroblastoma: detection of genomic imbalances by comparative genomic
hybridization. Acta Neurochir 139: 839–844
Van Gele M, Van Roy N, Jauch A, Laureys G, Benoit Y, Schelfhout V, De Porter
CR, Brock P, Uyttebroeck A, Sciot R, Schuuring E, Versteeg R and Speleman F
(1997) Sensitive and reliable detection of genomic imbalances in human
neuroblastoma using comparative genomic hybridisation analysis. Eur J
Cancer 33: 1979–1982
Neuroendocrine tumours of the digestive system
Terris B, Meddeb M, Marchio A, Danglot G, Flejou JF, Belghiti J, Ruszniewski P
and Bernheim A (1998) Comparative genomic hybridization analysis of
sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes
Cancer 22: 50–56
Ovary
Arnold N, Hägele L, Walz L, Schempp W, Pfisterer J, Bauknecht T and Kiechle M
(1996) Over-represenation of 3q and 8q material and loss of 18q material are
recurrent findings in advanced human ovarian cancer. Genes Chromosomes
Cancer 16: 46–54
Iwabuchi H, Sakamoto M, Sakunaga H, Ma Y-Y, Carcangiu ML, Pinkel D, Yang-
Feng TL and Gray JW (1995) Genetic analysis of benign, low-grade, and high-
grade ovarian tumors. Cancer Res 55: 6172–6180
Riopel MA, Spellerberg A, Griffin CA and Perlman EJ (1998) Genetic analysis of
ovarian germ cell tumors by comparative genomic hybridization. Cancer Res
58: 3105–3110
Tapper J, Sarantaus L, Vahteristo P, Nevanlinna H, Hemmer S, Seppala M, Knuutila
S and Butzow R (1998) Genetic changes in inherited and sporadic ovarian
carcinomas by comparative genomic hybridization: extensive similarity except
for a difference at chromosome 2q24–q32. Cancer Res 58: 2715–2719
Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, Yahushiji M and Testa JR
(1997) Comparative genomic hybridisation detects frequent overrepresentation
of chromosomal material from 3q26, 8q24 and 20q13 in human ovarian
carcinomas. Genes Chromosomes Cancer 20: 320–328
Tapper J, Bützow R, Wahlstöm T, Seppälä M and Knuutila S (1997) Evidence for
divergence of DNA copy number changes in serous, mucinous and
endometrioid ovarian carcinomas. Br J Cancer 75: 1782–1787
Pancreas
Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M
and Horii A (1997) Frequent gain of copy number on the long arm of
chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes
Cancer 19: 161–169
Mahlamäki EH, Höglund M, Gorunova L, Karhu R, Dawiskiba S, Andrén-Sandberg
Å, Kallionemi OP and Johansson B (1997) Comparative genomic hybridisation
reveals frequent gains of 20q, 8q, 11q, 12p and 17q, and losses of 18q, 9p and
15q in pancreatic cancer. Genes Chromosomes Cancer 20: 383–391
Solinas-Toldo S, Wallrapp C, Müller-Pillasch F, Bentz M, Gress T and Lichter P
(1996) Mapping of chromosomal imbalances in pancreatic carcinoma by
comparative genomic hybridization. Cancer Res 56: 3803–3807
Parathyroid
Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RK and Arnold A (1998)
Novel chromosomal abnormalities identified by comparative genomic
hybridization in parathyroid adenomas. J Clin Endocr Metab 83: 1766–1770
Pituitary
Daniely M, Aviram A, Adams EF, Buchfelder M, Barkai G, Fahlbusch R, Goldman
B and Friedman E (1998) Comparative genomic hybridization analysis of
nonfunctioning pituitary tumors. J Clin Endocr Metab 83: 1801–1805
Prostate
Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB and Jensen RH
(1994) Comparative genomic hybridization, allelic imbalance, and fluorescence
in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes
Cancer 11: 153–162
Nupponen NN, Kakkola L, Koivisto P and Visakorpi T (1998) Genetic alterations in
hormone-refractory recurrent prostate carcinomas. Am J Pathol 153: 141–148
Joos S, Bergerheim USR, Pan Y, Matsuyama H, Bentz M, du Manoir S and Lichter
P (1995) Mapping of chromosomal gains and losses in prostate cancer by
comparative genomic hybridization. Genes Chromosones Cancer 14: 267–276
Visakorpi T, Kallioniemi AH, Syvänen A-C, Hyytinen ER, Karhy R, Tammela T,
Isola J and Kallioniemi O-P (1995) Genetic changes in primary and recurrent
prostate cancer by comparative genomic hybridization. Cancer Res 55:
342–347
Renal
Bentz M, Bergerheim UR, Li C, Joos S, Werner CA, Baudis M, Gnarra J, Merino
MJ, Zbar B, Linehan WM and Lichter P (1996) Chromosome imbalances in
papillary renal cell carcinoma and first cytogenetic data of familial cases
analyzed by comparative genomic hybridization. Cyto Cell Genet 75: 17–21
Gronwald J, Storkel S, Holtgreve Grez H, Hadaczek P, Brinkschmidt C, Jauch A,
Lubinski J and Cremer T (1997) Comparison of DNA gains and losses in
primary renal clear cell carcinomas and metastatic sites: importance of 1q and
3p copy number changes in metastatic events. Cancer Res 57: 481–487
872 PH Rooney et al
British Journal of Cancer (1999) 80(5/6), 862–873 © Cancer Research Campaign 1999CGH in solid tumours 873
British Journal of Cancer (1999) 80(5/6), 862–873 © Cancer Research Campaign 1999
Moch H, Presti JC, Sauter G, Buchholz N, Jordan P, Mihatsch MJ and Waldman FM
(1996) Genetic aberrations detected by comparative genomic hybridization are
associated with clinical outcome in renal cell carcinoma. Cancer Res 56: 27–30
Presti JC, Moch H, Reuter VE, Huynh D and Waldman FM (1996) Comparative
genomic hybridization for genetic analysis of renal oncocytomas. Genes
Chromosomes Cancer 17: 199–204
Presti JC, Moch H, Reuter VE, Cordoncardo C and Waldman FM (1996) Renal-cell
carcinoma genetic-analysis by comparative genomic hybridization and
restriction fragment length polymorphism analysis. J Urol 156: 281–285
Rhabdomyosarcoma
Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-
Jones K and Shipley J (1996) Gains, losses, and amplification of genomic
material in rhabdomyosarcoma analyzed by comparative genomic
hybridization. Cancer Res 56: 3320–3224
Sarcoma
Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, Bohling T,
AskoSeljavaara S, Blomqvist C, Elomaa I, Karaharju E, Kivioja AH, Siimes
MA, Tukiainen E, Caballin MR, Myklebost O and Knuutila S (1997) Recurrent
gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic
hybridization. Br J Cancer 75: 1403–1409
Forus A, Olde Weghuis D, Smeets D, Fodstad Ø, Myklebost O and van Kessel A-G
(1995) Comparative genomic hybridization analysis of human sarcomas: 1.
Occurrence of genomic imbalances and identification of a novel major
amplicon at 1q21-q22 in soft tissue sarcomas. Genes Chromosomes Cancer 14:
8–14
Forus A, Olde Weghuis D, Smeets D, Fodstad Ø, Myklebost O and van Kessel AG
(1995) Comparative genomic hybridization analysis of human sarcomas: II.
Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes
Chromosomes Cancer 14: 15–21
KiuruKuhlefelt S, ElRifai W, SarlomoRikala M, Knuutila S and Miettinen M (1998)
DNA copy number changes in alveolar soft part sarcoma: a comparative
genomic hybridization study. Mod Path 11: 227–231
Larramendy ML, Tarkkanen M, Blomqvist C, Virolainen M, Wiklund T,
AskoSelijavaara S, Elomaa I and Knuutila S (1997a) Comparative genomic
hybridization of malignant fibrous histiocytoma reveals a novel prognostic
marker. Am J Pathol 151: 1153–1161
Larramendy ML, Valle J, Tarkkanen M, Kivioja AH, Karaharju E, Salmivalli T,
Elomma I and Knuutila S (1997b) No DNA copy number changes in
osteochondromas: a comparative genomic hybridization study. Cancer Genet
Cytogenet 97: 76–78
Packenham JP, duManoir S, Schrock E, Risinger JI, Dixon D, Denz DN, Evans JC,
Berchuck A, Barrett JC, Devereux TR and Ried T (1997) Analysis of genetic
alterations in uterine leiomyomas and leiomyosarcomas by comparative
genomic hybridization. Mol Carcinogen 19: 273–279
Szymanska J, Tarkkanen M, Wiklund T, Virolainen M, Blomqvist C, Asko-
Seljavaara S, Tukiainen E, Elomaa I and Knuutila S (1996) Gains and losses of
DNA sequences in liposarcomas evaluated by comparative genomic
hybridization. Genes Chromosomes Cancer 15: 89–94
Szymanska J, Mandahl N, Mertens F, Tarkkanen M, Karaharju E and Knuutila S
(1996) Ring chromosomes in parosteal osteosarcoma contain sequences from
12q13–15: a combined cytogenetic and comparative genomic hybridization
study. Genes Chromosomes Cancer 16: 31–34
Testicular
Decker H-JH, Neuhaus C, Jauch A, Speicher M, Ried T, Bujard M, Brauch H,
Störkel S, Stöckle M, Selger B and Huber C (1996) Detection of a germline
mutation and somatic homozygous loss of the von Hippel-Lindau tumor-
suppressor gene in a family with a de novo mutation. A combined genetic
study, including cytogenetics, PCR/SSCP, FISH, and CGH. Hum Genet 97:
770–776
Korn WM, Olde Weghuis DEM, Suijkerbuijk RF, Schmidt U, Otto T, du Manoir S,
van Kessel AG, Harstrick A, Seeber S and Bechre R (1996) Detection of
chromosomal DNA gains and losses in testicular germ cell tumours by
comparative genomic hybridization. Genes Chromosomes Cancer 17: 78–87
Mostert MMC, van de Pol M, Olde Weighuis D, Suijkerbuijk RF, van Kessel AG,
van Echten J, Oosterhuis JW and Looijenga LHJ (1996) Comparative genomic
hybridization of germ cell tumors of the adult testis: confirmation of karyotypic
findings and identification of a 12p-amplicon. Cancer Genet Cytogenet 89:
146–152
Ottesen AM, Kirchhoff M, Rajpert EW, Maahr J, Gerdes T, Rose H, Lundsteen C,
Petersen PM, Philip J and Skakkebaek NE (1997) Detection of chromosomal
aberrations in seminomatous germ cell tumours using comparative genomic
hybridisation. Genes Chromosomes Cancer 20: 412–418
Speicher MR, Jauch A, Walt H, du Manoir S, Ried T, Jochum W, Sulser T and
Cremer T (1995) Correlation of microscopic phenotype with genotype in a
formalin-fixed, paraffin-embedded testicular germ cell tumor with universal
DNA amplification, comparative genomic hybridization, and interphase
cytogenetics. Am J Pathol 146: 1332–1340
Uveal melanoma
Ghazvini S, Char DH, Kroll S, Waldman FM and Pinkel D (1996) Comparative
genomic hybridization analysis of archival formalin-fixed paraffin-embedded
uveal melanomas. Cancer Genet Cytogenet 90: 95–101
Speicher MR, Prescher G, du Manoir S, Jauch A, Horsthemke B, Bornfeld R,
Becher R and Cremer T (1994) Chromosomal gains and losses in uveal
melanomas detected by comparative genomic hybridization. Cancer Res 54:
3817–3838
Wilms’ tumour
Steenman M, Redeker B, deMeulemeester M, Wiesmeijer K, Voute PA, Westerveld
A, Slater R and Mannens M (1997) Comparative genomic hybridization
analysis of Wilms’ tumors. Cytogenet Cell Genet 77: 296–303
Valentine RAAM, Li H, Boyett JM, Shearer P, Grundy P, Shapiro DN and Look T
(1996) Identification of novel regions of deletion in familial Wilms’ tumor by
comparative genomic hybridization. Cancer Res 56: 3837–3841